We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CDER Reorganization Enters New Phase, Naming Three New Offices
CDER Reorganization Enters New Phase, Naming Three New Offices
The FDA has begun the second phase of its CDER reorganization efforts aimed improving drug reviews, including three new offices to handle medicines for cancers, infectious diseases and neurological disorders.